Wall Street expects a year-over-year decline in earnings on higher revenues when Pfizer (PFE) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 30. On the other ...

Neither is a leader right now, but one of them might be on track to change that.Both Pfizer (PFE 0.88%) and Roche Holdings (RHHBY -0.18%) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes of Novo Nordisk and Eli Lilly.Still, both have ongoing plans to develop weight loss pills. If those plans pan out, the returns are likely to be enormous. So which of these dark ...

The pharma's latest push to develop a weight loss pill isn't going well.On July 11, Pfizer (PFE 0.88%) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the move could make it a direct competitor to the weight loss market's tycoons, Novo Nordisk and Eli Lilly.Alas, shareholders are more likely to be left wanting than they are to experien ...

Loading...Loading...Pfizer Inc PFE, one of the world’s largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.Currently, PFE stock is trading at around $30, showing a year-to-date gain of 2.6%, despite being down 16% over the past year.Chart created using Benzinga ProThe golden cross, where the short-term moving average crosses above the long-term moving average, is viewed by traders as a bullish signal.Ch ...

For Immediate ReleaseChicago, IL – July 17, 2024 – Today, Zacks Equity Research discusses Eli Lilly (LLY) , Novo Nordisk (NVO) , Merck (MRK) and Pfizer (PFE) .Industry: Big PharmaLink: https://www.zacks.com/commentary/2302224/4-large-drug-stocks-to-watch-as-innovation-ma-pick-upThe drug and biotech industry is showing some promising trends in 2024, driven by an increase in mergers and acquisitions (M&A) and positive pipeline news. Large drugmakers have several robust revenue streams and are mostly profitabl ...

Medical Properties Trust's yield looks appealing, but it wouldn't have made up for the stock's 70% decline over the last three years.You've probably thought about whether that 13%-yielding stock could be a steal of a deal. All that dividend income could be significant. And so what if you lose money on the stock -- the dividend income could help make up for it. Plus, if things turn out well, the stock could even rise in value, giving you some great returns along with all that dividend income.That's undoubted ...

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with ...

Pfizer (PFE) announced that it has selected its preferred once-daily modified-release formulation of danuglipron, its oral GLP-1 receptor agonist, for further development as a weight loss pill based on encouraging results from an ongoing study. It evaluated several formulations of danuglipron and said that one showed “the most favorable profile.” Pfizer, however, did not announce any detailed clinical data from the study.In the second half of the year, Pfizer will conduct dose optimization studies on multip ...

Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice-daily version of the drug late last year.The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lillyand Novo Nordisk that will offer patients a more convenient alternative to injections.Some analysts expect the weight-loss drug market, currently dominated by Novo Nordisk’s ...

Key TakeawaysPfizer shares rose as the company said it would be moving forward with studies of a once-a-day oral weight-loss pill after testing its modified release formulation.The pill has the same GLP-1 receptor agonists used in the injectable obesity treatments from Novo Nordisk and Eli Lilly.Pfizer reported the drug was successful when given twice a day, but caused adverse side effects. Shares of Pfizer (PFE) advanced as the drug maker announced that it was moving forward with research into a potential ...